Given the devastating consequences of Alzheimers and the difficulties that some drug makers have encountered trying to develop treatments the slightest bit of positive data is sometimes greeted with outsized enthusiasm And this is why positive interim results from an earlystage study of a Biogen Idec medication caused its stock to rise  yesterday Just the same the report was met with caution underlying an ongoing debate about drugs that attack amyloid plaques in the brain The study is testing the drug against a placebo in  patients with early forms of Alzheimers Interim results showed a drop in beta amyloid levels in the brain and a statistically significant effect on cognition after  weeks of treatment Wall Street of course is watching this closely since there is a huge unmet need So what do the wags say